USA - New York Stock Exchange - NYSE:GRDN - US40145W1018 - Common Stock
The current stock price of GRDN is 29.6 USD. In the past month the price increased by 1.14%. In the past year, price increased by 17.28%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MGRX | MANGOCEUTICALS INC | N/A | 15.16M | ||
| SRXH | SRX HEALTH SOLUTIONS INC | N/A | 10.99M |
Guardian Pharmacy Services, Inc. engages in the provision of client service and resident care to long-term care communities. The company is headquartered in Atlanta, Georgia and currently employs 3,400 full-time employees. The company went IPO on 2024-09-26. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
GUARDIAN PHRMCY SERVICES-A
300 Galleria Parkway SE, Suite 800
Atlanta GEORGIA US
Employees: 3400
Phone: 14048100089
Guardian Pharmacy Services, Inc. engages in the provision of client service and resident care to long-term care communities. The company is headquartered in Atlanta, Georgia and currently employs 3,400 full-time employees. The company went IPO on 2024-09-26. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
The current stock price of GRDN is 29.6 USD. The price increased by 0.95% in the last trading session.
GRDN does not pay a dividend.
GRDN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
GRDN stock is listed on the New York Stock Exchange exchange.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRDN.
GUARDIAN PHRMCY SERVICES-A (GRDN) has a market capitalization of 1.87B USD. This makes GRDN a Small Cap stock.
ChartMill assigns a technical rating of 8 / 10 to GRDN. When comparing the yearly performance of all stocks, GRDN is one of the better performing stocks in the market, outperforming 74.73% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to GRDN. GRDN has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months GRDN reported a non-GAAP Earnings per Share(EPS) of 0.63. The EPS increased by 139.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.9% | ||
| ROA | 10.32% | ||
| ROE | 21.9% | ||
| Debt/Equity | 0 |
10 analysts have analysed GRDN and the average price target is 34.68 USD. This implies a price increase of 17.16% is expected in the next year compared to the current price of 29.6.
For the next year, analysts expect an EPS growth of 155.83% and a revenue growth 14.6% for GRDN